Search Within

Survivorship Research

Formats
  1. Journal Article (9003)
  2. Meeting Abstract (5248)
  3. Book Section (579)
  4. Review (366)
  5. Editorial (234)
  6. Research Letter (138)
  7. Conference Paper (104)
  8. Correspondence (92)
  9. Guidelines (90)
  10. Miscellaneous (78)
  11. Book Whole (30)
Groups
  1. Department of Medicine (9324)
  2. Population Sciences Research Program (5752)
  3. Solid Tumor Oncology Division (5243)
  4. Surgery (5199)
  5. Epidemiology and Biostatistics (3665)
  6. Division of Subspecialty Medicine (3268)

More Groups

People
  1. Clifford Hudis (905)
  2. Kenneth Offit (792)
  3. Michael Zelefsky (755)
  4. Sergio Giralt (702)
  5. Mark Robson (682)
  6. Joachim Yahalom (634)

More People

Years
  1. 2025 (382)
  2. 2024 (844)
  3. 2023 (892)
  4. 2022 (906)
  5. 2021 (922)
  6. 2020 (933)

More Years

Publications
  1. Journal of Clinical Oncology (1892)
  2. International Journal of Radiation Oncology, Biology, Physics (912)
  3. Blood (723)
  4. Annals of Surgical Oncology (602)
  5. Cancer (334)
  6. Cancer Research (333)

More Publications

Publishers
  1. Elsevier Inc. (2394)
  2. American Society of Clinical Oncology (2041)
  3. Springer (1558)
  4. Wiley Blackwell (816)
  5. Oxford University Press (792)
  6. American Society of Hematology (790)

More Publishers

Results (15962)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparative real-world outcomes of commercial CD19-directed CAR T-cell therapies in large B-cell lymphoma
    Meeting Abstract

    Deschênes-Simard, X.; Bromberg, M.; Devlin, S. M.; Katz, O. B.; Ip, A.; Marcus, R.; Avigdor, A.; Ballweg, A.; Rabinovich, E.; Alhomoud, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A medical chart review of healthcare costs in patients with systemic amyloid light chain amyloidosis by Mayo 2012 stage in the United States
    Meeting Abstract

    Gertz, M. M. A.; Landau, H. J.; Sanchorawala, V.; Bhutani, M.; Zonder, J. A.; Rosenzweig, M.; Magee, G.; Campos, C.; Yermilov, I.; Chang, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Emergency Medicaid policies enabling equitable access to healthcare coverage for undocumented individuals with hematologic malignancies across the United States
    Meeting Abstract

    Dubey, M.; Santos, P. M. G.; Feldman, K. E.; Narayan, A.; Persaud, S.; Santos, J.; Smith, M.; Anderson, E.; Hong, A.; Yabroff, K. R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Isatuximab in relapsed AL amyloidosis: Results of a prospective phase II trial (SWOG S1702)
    Meeting Abstract

    Parker, T. L.; Rosenthal, A.; Sanchorawala, V.; Landau, H.; Campagnaro, E. L.; Kapoor, P.; Neparidze, N.; Girnius, S.; Hagen, P.; Scott, E. C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial
    Meeting Abstract

    Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A Proof-of-principle of split-course bridging radiotherapy (SC-BRT) prior to CAR T-cell therapies for relapsed or refractory B-cell lymphomas: A phase 1a pilot cohort
    Meeting Abstract

    Imber, B. S.; Brosoff, A.; Roszak, E.; McAvoy, D.; Hosszu, K. K.; Boardman, A. P.; Dahi, P. B.; Shah, G. L.; Scordo, M.; Park, J. H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Investigating the novel combination of the innate cell engager (ICE®) acimtamig with off-the-shelf allogeneic natural killer cells AlloNK® in relapsed or refractory classical Hodgkin lymphoma (R/R cHL): Initial results of the phase 2 Luminice-203
    Meeting Abstract

    Maakaron, J.; Modi, D.; Mei, M. T.; Feldman, T.; Shah, G. L.; Mehta, A. N.; Sauter, C. S.; Khanal, R.; Barta, S. K.; Emig, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Very low dose radiotherapy (VLDRT) with 4 Gy for potentially-curable indolent non-Hodgkin lymphomas
    Meeting Abstract

    Mankuzhy, N. P.; Imber, B. S.; Pammer, P.; Fregonese, B.; Cajo, A.; Cederquist, G.; Dreyfuss, A.; Lapen, K.; Patel, R. R.; Moore, Z. R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • When can we define cure after CAR-T therapy in LBCL? insights from serial landmark analyses
    Meeting Abstract

    Gomez-Llobell, M.; Shouval, R.; Brown, S.; Accav, N. G.; Devlin, S. M.; Corona, M.; Rejeski, K.; Rivas-Delgado, A.; Luna, A.; Luttwak, E.; more...
    Blood (2024)

    Fulltext@MSK | Save